Medically Integrated Pharmacy: Oncology Cost & Waste Reduction
- A proactive approach involving oncology-trained nurses is substantially reducing medication waste and promoting better use of drugs in cancer care, according to new research.
- The research highlights the critical role of medically integrated pharmacies (MIPs) in avoiding costs and reducing waste.
- The National Institutes of Health estimated that suboptimal medication use cost the U.S.
Oncology nurses are leading the charge to slash medication waste and costs in cancer care through chart reviews and proactive interventions, with a study revealing $1.9 million in savings.This insightful research underscores the crucial role of medically integrated pharmacies in optimizing oral oncology medication use. these pharmacies identify discrepancies before shipments, ensuring patients receive the right treatments, preventing unneeded costs, and improving patient outcomes. The findings featured by News Directory 3 highlight how such strategies contribute to the avoidance and reduction of medication waste. Explore how oncology nurses’ dedication delivers both financial and clinical benefits. Curious about the future of oncology cost reduction?
Oncology Nurses Reduce Medication Waste in Cancer Care, Saving Millions
Updated June 17, 2025
A proactive approach involving oncology-trained nurses is substantially reducing medication waste and promoting better use of drugs in cancer care, according to new research. These nurses conduct thorough chart reviews and reassessments before medication refills are dispensed, preventing unnecessary prescriptions and saving millions of dollars.
The research highlights the critical role of medically integrated pharmacies (MIPs) in avoiding costs and reducing waste. By identifying discrepancies before medications are shipped, these pharmacies ensure that patients receive the most appropriate and necessary treatments.This intervention is especially significant in oncology, where oral therapies are increasingly common.
The National Institutes of Health estimated that suboptimal medication use cost the U.S. $418 billion in 2012. Data from a cost avoidance and waste tracker tool showed that MIPs achieved net cost avoidance of $6,510,971.28, compared to $546,082.45 for external mail-order pharmacies. Among 37 practices, 768 waste events were reported, totaling $11,275,642.16 in drug waste. External mail-order pharmacies accounted for $8,935,612.15 of this waste, while $2,429,592.01 was attributed to MIPs.
Nurses at American Oncology Network (AON) Pharmacy reviewed charts for all specialty oncology medications due for refill from February to September 2023. They accessed electronic medical records, reviewed notes, labs, scans, and appointments, and completed reassessment care plans. When discrepancies were found, shipments were held, and providers were notified.
During the study period,152 interventions were documented,resulting in $1.9 million in cost avoidance. This figure includes savings for patients with cancer and the health care industry. Reasons for holding shipments included dose changes,therapy holds,disease progression,therapy changes,and patients in hospice or deceased.
the findings underscore the clinical and financial significance of oncology nurses’ role in reducing unnecessary medication fills. By providing high-quality care and improving clinical outcomes, they contribute to the avoidance and waste reduction of oral oncology medications throughout the cancer care continuum. This proactive approach not only benefits patients but also promotes financial sustainability within the health care system.
What’s next
The research will be presented at the 2025 Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, on June 19 and 20. Attendees will have the prospect to explore the latest advancements in oncology pharmacy, showcase clinical research, and exchange ideas. The hematology/oncology pharmacy Association (HOPA) BCOP Program will also be held in person on June 18, featuring topics such as acute leukemia and cellular therapy for solid tumors.